Rossari Biotech Balance Sheet Health

Financial Health criteria checks 5/6

Rossari Biotech has a total shareholder equity of ₹10.5B and total debt of ₹1.1B, which brings its debt-to-equity ratio to 10.1%. Its total assets and total liabilities are ₹15.7B and ₹5.2B respectively. Rossari Biotech's EBIT is ₹1.9B making its interest coverage ratio 9.8. It has cash and short-term investments of ₹677.9M.

Key information

10.1%

Debt to equity ratio

₹1.06b

Debt

Interest coverage ratio	9.8x
Cash	₹677.94m
Equity	₹10.48b
Total liabilities	₹5.24b
Total assets	₹15.72b

Recent financial health updates

No updates

Recent updates

One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically

Feb 10

Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture

Sep 23

Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)

Apr 06

Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues

Feb 19

Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%

Feb 17

I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease

Feb 10

Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal

Nov 24

With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting

Oct 12

Is Rossari Biotech Limited's (NSE:ROSSARI) Latest Stock Performance Being Led By Its Strong Fundamentals?

Dec 17

Rossari Biotech (NSE:ROSSARI) Is Growing Earnings But Are They A Good Guide?

Oct 26

Financial Position Analysis

Short Term Liabilities: ROSSARI's short term assets (₹8.4B) exceed its short term liabilities (₹4.2B).

Long Term Liabilities: ROSSARI's short term assets (₹8.4B) exceed its long term liabilities (₹996.9M).

Debt to Equity History and Analysis

Debt Level: ROSSARI's net debt to equity ratio (3.6%) is considered satisfactory.

Reducing Debt: ROSSARI's debt to equity ratio has increased from 3.7% to 10.1% over the past 5 years.

Debt Coverage: ROSSARI's debt is well covered by operating cash flow (40.9%).

Interest Coverage: ROSSARI's interest payments on its debt are well covered by EBIT (9.8x coverage).

Rossari Biotech Balance Sheet Health

Financial Health criteria checks 5/6

Key information

Recent financial health updates

Recent updates

Full year 2024 earnings: EPS misses analyst expectations

Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024

Now 20% undervalued

Price target increased by 9.0% to ₹852

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 17%

Price target decreased by 8.4% to ₹782

Second quarter 2024 earnings released: EPS: ₹5.97 (vs ₹4.34 in 2Q 2023)

Rossari Biotech Limited to Report Q2, 2024 Results on Oct 21, 2023

First quarter 2024 earnings released: EPS: ₹5.30 (vs ₹5.21 in 1Q 2023)

Rossari Biotech Limited to Report Q1, 2024 Results on Jul 29, 2023

Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent Director

Investor sentiment improves as stock rises 16%

Rossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023

Upcoming dividend of ₹0.50 per share at 0.1% yield

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Consensus revenue estimates fall by 13%

One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically

Price target decreased by 9.2% to ₹986

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent Director

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹4.34 (vs ₹4.77 in 2Q 2022)

Rossari Biotech Limited to Report Q2, 2023 Results on Nov 05, 2022

Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture

First quarter 2023 earnings released: EPS: ₹5.21 (vs ₹4.52 in 1Q 2022)

Rossari Biotech Limited to Report Q1, 2023 Results on Aug 06, 2022

Rossari Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Upcoming dividend of ₹0.50 per share

Full year 2022 earnings: EPS misses analyst expectations

Rossari Biotech Limited Recommended Final Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Rossari Biotech Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Rossari Biotech Limited, Annual General Meeting, Jul 15, 2022

Price target decreased to ₹1,252

Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)

Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues

Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to ₹1,330

I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease

Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal

Second quarter 2022 earnings released: EPS ₹4.77 (vs ₹4.07 in 2Q 2021)

With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting

Insider recently sold ₹2.1m worth of stock

Price target increased to ₹1,270

First quarter 2022 earnings released: EPS ₹4.52 (vs ₹3.19 in 1Q 2021)

Rossari Biotech Reportedly in Advanced Talks to Acquire Specialty Chemicals Business

Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion.

Full year 2021 earnings released: EPS ₹15.56 (vs ₹13.42 in FY 2020)

Investor sentiment improved over the past week

Rossari Biotech Limited announced that it expects to receive INR 2.999997816 billion in funding from Malabar Investments, LLC, State Bank of India, Asset Management Arm and other investors

Investor sentiment improved over the past week

New 90-day high: ₹991

Third quarter 2021 earnings released: EPS ₹4.16

Rossari Biotech Limited to Report Q3, 2021 Results on Jan 23, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹859

Is Rossari Biotech Limited's (NSE:ROSSARI) Latest Stock Performance Being Led By Its Strong Fundamentals?

New 90-day high: ₹838

Rossari Biotech (NSE:ROSSARI) Is Growing Earnings But Are They A Good Guide?

First half earnings released

Rossari Biotech Limited to Report Q2, 2021 Results on Oct 24, 2020

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies